Meloxicam Safety in Psoriasis Patients

Introduction to Meloxicam Use

The American Academy of Dermatology recommends avoiding NSAIDs, including meloxicam, in patients with psoriasis, as they can trigger or exacerbate psoriatic disease 1

Long-term NSAID use is associated with a hazard ratio of 2.10 (95% CI: 1.11-3.96) for developing psoriatic arthritis compared to non-users, although the source of this data is not explicitly cited in the provided text, it is mentioned in the context of 1

The American College of Rheumatology and EULAR guidelines suggest that NSAIDs may be used cautiously in psoriatic arthritis patients for symptomatic relief of musculoskeletal manifestations, but they provide no disease-modifying benefit and carry the risk of worsening skin disease 2, 3
The 2020 EULAR guidelines state that NSAIDs "may be used to relieve musculoskeletal signs and symptoms" in psoriatic arthritis, specifically for the arthritic component, not the skin disease 2, 3
When patients have insufficient response to NSAIDs for enthesitis, dactylitis, or axial disease, guidelines recommend escalating to biologic DMARDs rather than continuing NSAID therapy 2, 4

For psoriatic arthritis with active skin disease, NSAIDs should be used only as short-term bridging therapy while initiating DMARDs, and patients should be monitored closely for psoriasis flares 1, 2
For psoriatic arthritis with minimal/controlled skin disease, NSAIDs may be used for symptomatic relief, but their duration and dose should be limited, and patients should be maintained with vigilance for new skin lesions or worsening plaques 1, 2, 3, 4